The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma

類似資料

• Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
  著者:: Papanikolaou, Xenofon, 等
  出版事項: (2014)
• Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
  著者:: Shaughnessy, John D., 等
  出版事項: (2011)
• PHF19 inhibition as a therapeutic target in Multiple Myeloma
  著者:: Schinke, Carolina D., 等
  出版事項: (2021)
• The molecular characterization and clinical management of multiple myeloma in the post-genome era
  著者:: Zhou, Y, 等
  出版事項: (2009)
• High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
  著者:: Zhan, Fenghuang, 等
  出版事項: (2008)